Hi Barry,
Every study that gives info about which patients that do respond is important. A response rate of 93% is very, very good
.
The patients have to be carefully selected. As you see yound age, low IPSS score and the presence of Human leukocyte antigen DR15A are inclusion criteria for treatment in this study.
In other studies only 30% of the patients have responded when thay have got Campath (Alemtuzumab) so those of us that are young with low IPSS could ask for examination of their Human leukocyte antigen DR15A. If it is positive they ought to try Campath.
Kind regards
Birgitta-A